Aprotinin modifies left ventricular contractility and cytokine release after ischemia-reperfusion in a dose-dependent manner in a murine model

Anesthesia and Analgesia

Volumn 108, Issue 2, 2009, Pages 399-406

  McEvoy, Matthew D ^a   Sabbagh, Michel J ^a   Taylor, Anna Greta ^a   Zavadzkas, Juozas A ^a   Koval, Christine N ^a   Stroud, Robert E ^a   Ford, Rachael L ^a   McLean, Julie E ^a   Reeves, Scott T ^a   Mukherjee, Rupak ^a   Spinale, Francis G ^a,b,c  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b RALPH H JOHNSON VA MEDICAL CENTER   (United States)

^c MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APROTININ; INTERLEUKIN 10; INTERLEUKIN 6; TUMOR NECROSIS FACTOR; CYTOKINE; HEMOSTATIC AGENT; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CALCULATION; COMPLIANCE (PHYSICAL); CYTOKINE RELEASE; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG MECHANISM; HEART MUSCLE ISCHEMIA; HEART MUSCLE REPERFUSION; HEART PROTECTION; HEART VENTRICLE CONTRACTILITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; ANIMAL; BLOOD; ELASTICITY; HEART ARRHYTHMIA; HEART CONTRACTION; HEART LEFT VENTRICLE FUNCTION; HEMODYNAMICS; KINETICS; METABOLISM; PATHOPHYSIOLOGY; PHYSIOLOGY; REPERFUSION INJURY;

ANIMALS; APROTININ; ARRHYTHMIAS, CARDIAC; CYTOKINES; DOSE-RESPONSE RELATIONSHIP, DRUG; ELASTICITY; HEMODYNAMICS; HEMOSTATICS; KINETICS; MICE; MYOCARDIAL CONTRACTION; MYOCARDIAL REPERFUSION INJURY; TUMOR NECROSIS FACTOR-ALPHA; VENTRICULAR FUNCTION, LEFT;

EID: 59649098349     PISSN: 00032999     EISSN: None     Source Type: Journal    
DOI: 10.1213/ane.0b013e31818cdb13     Document Type: Article

References (27)

1. Sedrakyan A, Treasure T, Elefteriades JA. Effect of aprotinin on clinical outcomes in a coronary arterty bypass graft surgery: a systematic review and meta-analysis of randomized clinical trials. J Thorac Cardiovasc Surg 2004;128:442-8
2. Levi M, Cromheecke ME, de Jonge E, Prins MH, de Mol BJ, Briet E, Buller HR. Pharmacological strategies to decrease excessive blood loss in cardiac surgery: a meta-analysis of clinically relevant endpoints. Lancet 1999;354:1940-7
3. Mangano DT, Tudor IC, Dietzel C. The risk associated with aprotinin in cardiac surgery. NEJM 2006;354:353-65
4. Fergusson DA, He'bert PC, Mazer CD, Fremes S, MacAdams C, Murkin JM, Teoh K, Duke PC, Arellano R, Blajchman MA, Bussieres JS, Côte' D, Karski J, Martineau R, Robblee JA, Rodger M, Wells G, Clinch J, Pretorius R, BART Investigators. A comparison of aprotinin and lysine analogues in high-risk cardiac surgery. N Engl J Med 2008;358:2319-31
5. Bull D, Connors R, Albanil A, Reid B, Neumayer LA, Nelson R, Stringham JC, Karwande SV. Cardiopulmonary Support and Physiology. Aprotinin preserves myocardial biochemical function during cold storage through suppression of tumor necrosis factor. J Thorac Cardiovasc Surg 2000;119:242-50
6. Bull D, Maurer J. Aprotinin and preservation of myocardial function after ischemia-reperfusion injury. Ann Thorac Surg 2003;75:S735-S739
7. Meldrum DR. Tumor necrosis factor in the heart. Am J Physiol 1998;274:R577-R595
8. Prabhu SD. Cytokine-induced modulation of cardiac function. Circ Res 2004;95:1140-53
9. Ren G, Dewald O, Frangogiannis NG. Inflammatory mechanisms in myocardial infarction. Curr Drug Targets Inflamm Allergy 2003;2:242-56
10. Greilich PE, Okada K, Latham P, Kumar RR, Jessen ME. Aprotinin but not epsilon-aminocaproic acid decreases interleukin-10 after cardiac surgery with extracorporeal circulation: randomized, double-blind, placebo-controlled study in patients receiving aprotinin and epsilon-aminocaproic acid. Circulation 2001;104:I265-I269
11. Turkoz A, Cigli A, But K, Sezgin N, Turkoz R, Gulcan O, Ersoy MO. The effects of aprotinin and steroids on generation of cytokines during coronary artery surgery. J Cardiothorac Vasc Anesth 2001;15:603-10
12. Krombach RS, Clair MJ, Hendrick JW, Houck WV, Zellner JL, Kribbs SB, Whitebread S, Mukherjee R, de Gasparo M, Spinale FG. Angiotensin converting enzyme inhibition, AT1 receptor inhibition, and combination therapy with pacing induced heart failure: effects on left ventricular performance and regional blood flow patterns. Cardiovasc Res 1998;38:631-45
13. van Oeveren W, Jansen NJ, Bidstrup BP, Royston D, Westaby S, Neuhof H, Wildevuur CR. Effects of aprotinin on hemostatic mechanisms during cardiopulmonary bypass. Ann Thorac Surg 1987;44:640-5
14. Royston D, Bidstrup BP, Taylor KM, Sapsford RN. Effect of aprotinin on need for blood transfusion after repeat open-heart surgery. Lancet 1987;2:1289-91
15. Royston D, Cardigan R, Gippner-Steppert C, Jochum M. Is perioperative plasma aprotinin concentration more predictable and constant after a weight-related dose regimen? Anesth Analg 2001;92:830-6
16. McCarthy RJ, Tuman K, O'Connor C, Ivankovish AD. Aprotinin pretreatment diminished postischemic myocardial contractile dysfunction in dogs. Anesth Analg 1999;89:1096-101
17. Khan TA, Bianchi C, Araujo E, Voisine P, Xu SH, Feng J, Li J, Sellke FW. Aprotinin preserves cellular junctions and reduces myocardial edema after regional ischemia and cardioplegic arrest. Circulation 2005;112:I196 -I201
18. Ikonomidis JS, Hendrick JW, Parkhurst AM, Herron AR, Escobar PG, Dowdy KB, Stroud RE, Hapke E, Zile MR, Spinale FG. Accelerated LV remodeling after myocardial infarction in TIMP-1-deficient mice: effects of exogenous MMP inhibition. Am J Physiol Heart Circ Physiol 2005; 288:H149-H158
19. Suga H, Sagawa K. Mathematical interrelationship between instantaneous ventricular pressure-volume ratio and myocardial force-velocity relation. Ann Biomed Engl 1972;1:160 - 81
20. Feldman MD, Erikson JM, Mao Y, Korcarz CE, Lang RM, Freeman GL. Validation of a mouse conductance system to determine LV volume: comparison to echocardiography and crystals. Am J Physiol Heart Circ Physiol 2000;279:H1698- H1707
21. Chang KC, Peng YI, Lee FC, Tseng YZ. Effects of food restriction on systolic mechanical behavior of the ventricular pump in middle-aged and senescent rats. J Gerontol A Biol Sci Med Sci 2001;56:B108-B114
22. Giomarelli P, Scolletta S, Borrelli E, Biagioli B. Myocardial and lung injury after cardiopulmonary bypass: role of interleukin (IL)-10. Ann Thorac Surg 2003;76:117-23
23. Blancke F, Claeys MJ, Jorens P, Vermeiren G, Bosmans J, Wuyts FL, Vrints CJ. Systemic inflammation and reperfusion injury in patients with acute myocardial infarction. Mediators Inflamm 2005;2005:385-9
24. Harmon D, Lan W, Shorten G. The effect of aprotinin on hypoxia-reoxygenation-induced changes in neutrophil and endothelial function. Eur J Anaesthes 2004;21:973-9
25. Gott JP, Cooper WA, Schmidt FE, Brown WM, Wright CE, Merlino JD, Fortenberry JD, Clark WS, Guyton RA. Modifying risk for extracorporeal circulation: trial of four antiinflammatory strategies. Ann Thorac Surg 1998;66:747-54
26. Hill GE, Pohorecki R, Alonso A, Rennard S, Robbins R. Aprotinin reduces interleukin-8 production and lung neutrophil accumulation after cardiopulmonary bypass. Anesth Analg 1996;83:696-700
27. Beath SM, Nuttall GA, Fass DN, Oliver WC Jr, Ereth MG, Oyen LJ. Plasma aprotinin concentrations during cardiac surgery: full-versus half-dose regimens. Anesth Analg 2001;91:257-64